This article refers to:
Hurst KV, O’Callaghan JM, Handa A. Vascular Health and Risk Management. 2017:13 263–267.
On page 264, Table 2 states that the apixaban dose should be reduced in patients with mild hepatic impairment and that it is not indicated in patients with moderate-to-severe hepatic impairment. This is also stated in the text to the left of that table.
The authors amend this to:
Apixaban dose adjustment is not required in patients with mild or moderate hepatic impairment, however it should be used with caution in these patients and dose adjustment may be needed. Apixaban is not recommended in patients with severe hepatic impairment.